MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma

[1]  Yukiko Nakamura,et al.  Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Ochiai,et al.  Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms , 2009, Modern Pathology.

[3]  D. Kufe.  Functional targeting of the MUC1 oncogene in human cancers , 2009, Cancer biology & therapy.

[4]  A. Hartmann,et al.  Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. , 2008, Human pathology.

[5]  M. Sonobe,et al.  A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  S. Gendler,et al.  MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation , 2004, Oncogene.

[7]  A. Hölscher,et al.  MUC1 and Nuclear β-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis , 2004, Clinical Cancer Research.

[8]  T. Irimura,et al.  Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder , 2004, Clinical & Experimental Metastasis.

[9]  M. Oka,et al.  Increased expression of MUC1 in advanced pancreatic cancer , 2003, Journal of Gastroenterology.

[10]  J. Hanaoka,et al.  Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. , 2003, International journal of molecular medicine.

[11]  R. Pfeiffer,et al.  Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies , 2003, International journal of cancer.

[12]  M. Ghazizadeh,et al.  Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. , 2002, Japanese journal of clinical oncology.

[13]  K. Imai,et al.  Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: Its relationship with tumor progression and prognosis , 2002, Pathology international.

[14]  A. Giatromanolaki,et al.  Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance , 2002, Histopathology.

[15]  L. Sobin,et al.  Histological Typing of Tumours of the Thymus , 1999, World Health Organization. International Histological Classification of Tumours.

[16]  Levine,et al.  MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. , 1999, Molecular urology.

[17]  T. Irimura,et al.  Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  V. Apostolopoulos,et al.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. , 1997, The Journal of clinical investigation.

[19]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[20]  Y. Monden,et al.  Follow‐up study of thymomas with special reference to their clinical stages , 1981, Cancer.